Mangoceuticals, Inc.(MGRX)Earnings, Financials & Key Ratios
MGRX•NASDAQ
$0.35
$6M mkt cap·Price updated May 6, 2026
AboutMangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.Show more
- Revenue$616K-15.8%
- EBITDA-$7M+21.1%
- Net Income-$9M+5.5%
- EPS (Diluted)-4.40+48.7%
- Gross Margin61.7%+4.6%
- EBITDA Margin-1177.27%+6.3%
- Operating Margin-1294.42%-2.7%
- Net Margin-1413.6%-12.2%
- ROE-118.29%+91.1%
- ROIC-83.82%+97.3%
- Debt/Equity0.02-90.7%
- Interest Coverage-581.90
MGRX Key Insights
Mangoceuticals, Inc. (MGRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 3 (bottom 3%)
- ✗Shares diluted 84.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MGRX Price & Volume
Mangoceuticals, Inc. (MGRX) stock price & volume — 10-year historical chart
Loading chart...
MGRX Growth Metrics
Mangoceuticals, Inc. (MGRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-38.16%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-112.55%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM50.68%
Return on Capital
10 Years-607.22%
5 Years-607.22%
3 Years-607.22%
Last Year-107.84%
MGRX Peer Comparison
Mangoceuticals, Inc. (MGRX) competitors in Virtual Care and Digital Programs — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HIMS | 6.94B | 26.88 | 52.71 | 59% | 5.47% | 23.73% | 2.07 | |
 MNMD | 2.04B | 20.69 | -10.04 | -55.3% | ||||
 AMWL | 119.11M | 7.15 | -1.20 | -1.98% | -48.16% | -33.48% | 0.02 | |
 TDOC | 1.23B | 6.80 | -5.96 | -1.54% | -6.81% | -12.37% | 0.75 | |
 OPRX | 120.61M | 6.47 | 23.96 | 18.78% | 4.69% | 4.22% | 0.04 | |
 WELL | 151.66B | 216.47 | 155.73 | 35.82% | 12.31% | 3.49% | 0.49 | |
 DOCS | 5.17B | 25.69 | 23.14 | 19.98% | 37.54% | 24.45% | 0.01 | |
 PFE | 150.77B | 26.51 | 19.49 | -1.65% | 11.83% | 8.34% | 0.78 |
Compare MGRX vs Peers
Mangoceuticals, Inc. (MGRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MGRX Income Statement
Mangoceuticals, Inc. (MGRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
| Sales/Revenue | 0 | 8.94K | 731.49K | 615.87K | 466.91K |
| Revenue Growth % | - | - | 8083.16% | -15.81% | -38.16% |
| Cost of Goods Sold | 0 | 4.09K | 299.99K | 235.91K | 183.89K |
| COGS % of Revenue | - | 45.74% | 41.01% | 38.3% | - |
| Gross Profit | 0▲ 0% | 4.85K▲ 0% | 431.5K▲ 8796.9% | 379.96K▼ 11.9% | 283.01K▲ 0% |
| Gross Margin % | - | 54.26% | 58.99% | 61.7% | 60.61% |
| Gross Profit Growth % | - | - | 8796.93% | -11.94% | - |
| Operating Expenses | 17.52K | 2M | 9.65M | 8.35M | 19.63M |
| OpEx % of Revenue | - | 22333.95% | 1319.27% | 1356.12% | - |
| Selling, General & Admin | 17.52K | 2M | 5.42M | 7.9M | 10.91M |
| SG&A % of Revenue | - | 22333.95% | 740.53% | 1282.44% | - |
| Research & Development | 0 | 0 | 0 | 0 | 171.86K |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 4.23M | 453.79K | 1.95M |
| Operating Income | -17.52K▲ 0% | -1.99M▼ 11267.5% | -9.22M▼ 362.9% | -7.97M▲ 13.5% | -19.34M▲ 0% |
| Operating Margin % | - | -22279.7% | -1260.28% | -1294.42% | -4142.7% |
| Operating Income Growth % | - | -11267.48% | -362.89% | 13.53% | - |
| EBITDA | -17.52K | -1.99M | -9.19M | -7.25M | -17.34M |
| EBITDA Margin % | - | -22236.48% | -1256.88% | -1177.27% | -3714.81% |
| EBITDA Growth % | - | -11245.43% | -362.54% | 21.14% | -96.72% |
| D&A (Non-Cash Add-back) | 0 | 3.86K | 24.89K | 721.53K | 2M |
| EBIT | -17.52K | -1.99M | -8.12M | -8.69M | -20.19M |
| Net Interest Income | -181 | -6.47K | 0 | -13.7K | 366.75K |
| Interest Income | 0 | 0 | 0 | 0 | 13.7K |
| Interest Expense | 181 | 6.47K | 0 | 13.7K | -353.05K |
| Other Income/Expense | -181 | -6.47K | 6.47K | -735K | -480.48K |
| Pretax Income | -17.7K▲ 0% | -2M▼ 11187.8% | -9.21M▼ 361.1% | -8.71M▲ 5.5% | -19.82M▲ 0% |
| Pretax Margin % | - | -22352.11% | -1259.4% | -1413.77% | -4245.61% |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
| Net Income | -17.7K▲ 0% | -2M▼ 11187.8% | -9.21M▼ 361.1% | -8.71M▲ 5.5% | -19.82M▲ 0% |
| Net Margin % | - | -22352.11% | -1259.4% | -1413.6% | -4245.25% |
| Net Income Growth % | - | -11187.81% | -361.07% | 5.5% | -112.55% |
| Net Income (Continuing) | -17.7K | -2M | -9.21M | -8.71M | -19.82M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | -1.08K | -1.74K |
| EPS (Diluted) | -0.02▲ 0% | -1.73▼ 9679.1% | -8.58▼ 395.7% | -4.40▲ 48.7% | -1.72▲ 0% |
| EPS Growth % | - | -9679.1% | -395.7% | 48.73% | 50.68% |
| EPS (Basic) | -0.02 | -1.73 | -8.58 | -4.40 | - |
| Diluted Shares Outstanding | 997.67K | 1.15M | 1.07M | 1.98M | 11.52M |
| Basic Shares Outstanding | 997.67K | 1.15M | 1.07M | 1.98M | 11.52M |
| Dividend Payout Ratio | - | - | - | - | - |
MGRX Balance Sheet
Mangoceuticals, Inc. (MGRX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
| Total Current Assets | 22.55K | 694.61K | 818.46K | 75.59K | 598.22K |
| Cash & Short-Term Investments | 22.55K | 682.86K | 739.01K | 58.65K | 481.28K |
| Cash Only | 22.55K | 682.86K | 739.01K | 58.65K | 481.28K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - |
| Inventory | 0 | 0 | 18.5K | 0 | 0 |
| Days Inventory Outstanding | - | - | 22.51 | - | - |
| Other Current Assets | 0 | 0 | 0 | 16.94K | 116.94K |
| Total Non-Current Assets | 0 | 308.68K | 232.33K | 15.29M | 15.93M |
| Property, Plant & Equipment | 0 | 291.74K | 215.39K | 62.3K | 13.26K |
| Fixed Asset Turnover | - | 0.03x | 3.40x | 9.89x | 12.30x |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 15.23M | 15.92M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 16.94K | 16.94K | 0 | 0 |
| Total Assets | 22.55K▲ 0% | 1M▲ 4349.2% | 1.05M▲ 4.7% | 15.37M▲ 1362.8% | 16.53M▲ 0% |
| Asset Turnover | - | 0.01x | 0.70x | 0.04x | 0.03x |
| Asset Growth % | - | 4349.17% | 4.74% | 1362.75% | 8527.78% |
| Total Current Liabilities | 39.27K | 260.58K | 211.08K | 1.43M | 804.27K |
| Accounts Payable | 0 | 33.67K | 140.76K | 837.5K | 0 |
| Days Payables Outstanding | - | 3.01K | 171.27 | 1.3K | 1.38K |
| Short-Term Debt | 39.27K | 167.46K | 0 | 150K | 212.17K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 373K | 592.11K |
| Current Ratio | 0.57x | 2.67x | 3.88x | 0.05x | 0.05x |
| Quick Ratio | 0.57x | 2.67x | 3.79x | 0.05x | 0.05x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 128.68K | 64.96K | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 128.68K | 64.96K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 39.27K | 389.26K | 276.04K | 1.43M | 804.27K |
| Total Debt | 39.27K | 352.87K | 128.68K | 214.96K | 212.17K |
| Net Debt | 16.72K | -330K | -610.33K | 156.31K | -269.11K |
| Debt / Equity | - | 0.57x | 0.17x | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | - | -0.01x |
| Net Debt / EBITDA | - | - | - | - | 0.02x |
| Interest Coverage | -96.80x | -307.68x | - | -581.90x | 57.19x |
| Total Equity | -16.72K▲ 0% | 614.03K▲ 3772.4% | 774.75K▲ 26.2% | 13.95M▲ 1699.9% | 15.73M▲ 0% |
| Equity Growth % | - | 3772.43% | 26.18% | 1699.93% | 3969.36% |
| Book Value per Share | -0.02 | 0.53 | 0.72 | 7.05 | 1.36 |
| Total Shareholders' Equity | -16.72K | 614.03K | 774.75K | 13.95M | 15.73M |
| Common Stock | 800 | 1.34K | 2.14K | 325 | 1.39K |
| Retained Earnings | -17.7K | -2.02M | -11.23M | -20.81M | -37.88M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | -9.85K | -2.08K |
| Minority Interest | 0 | 0 | 0 | -1.08K | -1.74K |
MGRX Cash Flow Statement
Mangoceuticals, Inc. (MGRX) cash flow — operating, investing & free cash flow history
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
| Cash from Operations | -17.52K | -1.35M | -7M | -4.86M | -4.86M |
| Operating CF Margin % | - | -15063.41% | -956.59% | -789.74% | - |
| Operating CF Growth % | - | -7585.6% | -419.66% | 30.49% | -82.18% |
| Net Income | -17.7K | -2M | -9.21M | -8.71M | -19.82M |
| Depreciation & Amortization | 0 | 3.86K | 24.89K | 731.47K | 2.27M |
| Stock-Based Compensation | 0 | 234.09K | 624.46K | 248.68K | 1.15M |
| Deferred Taxes | 0 | -151.82K | 0 | 0 | 0 |
| Other Non-Cash Items | 181 | 546.54K | 1.52M | 2.2M | 10.65M |
| Working Capital Changes | 0 | 18.87K | 41.51K | 660.38K | -152.69K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | -5.29K |
| Change in Payables | 0 | 33.67K | 107.09K | 696.74K | 237.38K |
| Cash from Investing | 0 | -43.1K | -3.52K | 65K | 0 |
| Capital Expenditures | 0 | -43.1K | -3.52K | 0 | 0 |
| CapEx % of Revenue | - | 482.18% | 0.48% | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 65K | 0 |
| Cash from Financing | 40.07K | 2.05M | 7.06M | 4.13M | 6.31M |
| Debt Issued (Net) | 39.27K | 49.93K | -167.46K | 150K | 562.5K |
| Equity Issued (Net) | 800 | 1000K | 1000K | 1000K | 2.38M |
| Dividends Paid | 0 | 0 | 0 | -802.11K | -1.39M |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 1.02M | 802.11K | 2.69M |
| Net Change in Cash | 22.55K▲ 0% | 660.31K▲ 2828.2% | 56.15K▼ 91.5% | -680.35K▼ 1311.8% | 407.37K▲ 0% |
| Free Cash Flow | -17.52K▲ 0% | -1.39M▼ 7831.6% | -7M▼ 403.8% | -4.86M▲ 30.5% | -5.9M▲ 0% |
| FCF Margin % | - | -15545.59% | -957.07% | -789.74% | -1264.07% |
| FCF Growth % | - | -7831.62% | -403.8% | 30.53% | -8.65% |
| FCF per Share | -0.02 | -1.20 | -6.52 | -2.46 | -2.46 |
| FCF Conversion (FCF/Net Income) | 0.99x | 0.67x | 0.76x | 0.56x | 0.30x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
MGRX Key Ratios
Mangoceuticals, Inc. (MGRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|
| Return on Equity (ROE) | -669.02% | -1326.69% | -118.29% | -114.63% |
| Return on Invested Capital (ROIC) | -1051.76% | -3083.5% | -83.82% | -83.82% |
| Gross Margin | 54.26% | 58.99% | 61.7% | 60.61% |
| Net Margin | -22352.11% | -1259.4% | -1413.6% | -4245.25% |
| Debt / Equity | 0.57x | 0.17x | 0.02x | 0.02x |
| Interest Coverage | -307.68x | - | -581.90x | 57.19x |
| FCF Conversion | 0.67x | 0.76x | 0.56x | 0.30x |
| Revenue Growth | - | 8083.16% | -15.81% | -38.16% |
MGRX Frequently Asked Questions
Mangoceuticals, Inc. (MGRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Mangoceuticals, Inc. (MGRX) reported $0.5M in revenue for fiscal year 2024.
Mangoceuticals, Inc. (MGRX) saw revenue decline by 15.8% over the past year.
Mangoceuticals, Inc. (MGRX) reported a net loss of $19.8M for fiscal year 2024.
Dividend & Returns
Yes, Mangoceuticals, Inc. (MGRX) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.
Mangoceuticals, Inc. (MGRX) has a return on equity (ROE) of -118.3%. Negative ROE indicates the company is unprofitable.
Mangoceuticals, Inc. (MGRX) had negative free cash flow of $5.9M in fiscal year 2024, likely due to heavy capital investments.
Explore More MGRX
Mangoceuticals, Inc. (MGRX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates